8-K
filed October 2, 2024, 7:59 PM ET
ticker RXRX
CIK 0001601830
regulatory
confidence high
sentiment positive
materiality 0.65
FDA clears IND for Recursion's REC-1245, a first-in-class RBM39 degrader for solid tumors/lymphoma
RECURSION PHARMACEUTICALS, INC.
- FDA cleared IND for REC-1245, a potential first-in-class RBM39 degrader for biomarker-enriched solid tumors and lymphoma.
- Phase 1/2 trial to start Q4 2024 evaluating safety, tolerability, PK/PD, and monotherapy efficacy.
- Target identified via Recursion's AI platform; program advanced from target to IND in under 18 months.
- Initially addressable population estimated at >100,000 patients in the US and EU5.
- Preclinical data show RBM39 degradation induces splicing defects downregulating DNA Damage Response networks.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001601830-24-000165
- form_type
- 8-K
- ticker
- RXRX
- cik
- 0001601830
- company_name
- RECURSION PHARMACEUTICALS, INC.
- filed_at
- 2024-10-02T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:08.935792+00:00
- generated_at
- 2026-05-30T22:34:06.253438+00:00
- sec_items
- ["7.01", "9.01"]
- event_type
- regulatory
- sentiment
- positive
- materiality_score
- 0.65
- calibrated_materiality_score
- 0.65
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001601830-24-000165
- json_url
- https://secwatch.observer/filing/0001601830-24-000165.json
- markdown_url
- https://secwatch.observer/filing/0001601830-24-000165.md
- text_url
- https://secwatch.observer/filing/0001601830-24-000165.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1601830/000160183024000165/0001601830-24-000165-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1601830/000160183024000165/rxrx-20241002.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
GENC
Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing
GENCOR INDUSTRIES INC
June 1, 2026, 4:09 PM ET
regulatory
Items 3.01, 7.01, 9.01
same SEC item: 7.01, 9.01
same event type: regulatory
similar materiality
Filing page
SEC filing
NJR
NJNG files base rate case seeking $157.6M increase; offers 8.9% winter bill cut
NEW JERSEY RESOURCES CORP
June 1, 2026, 4:03 PM ET
regulatory
Items 7.01, 9.01
same SEC item: 7.01, 9.01
same event type: regulatory
similar materiality
Filing page
SEC filing
ELTP
Elite Pharmaceuticals files ANDA for generic anticoagulant; $26B brand market, no generic available
ELITE PHARMACEUTICALS INC /NV/
June 1, 2026, 7:00 AM ET
regulatory
Items 7.01, 9.01
same SEC item: 7.01, 9.01
same event type: regulatory
similar materiality
Filing page
SEC filing
ATNM
Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26
Actinium Pharmaceuticals, Inc.
May 29, 2026, 5:10 PM ET
regulatory
Items 3.01, 7.01, 9.01
same SEC item: 7.01, 9.01
same event type: regulatory
similar materiality
Filing page
SEC filing
BDX
BD resumes ChloraPrep shipments after voluntary hold; all final release testing acceptable
BECTON DICKINSON & CO
May 29, 2026, 8:39 AM ET
regulatory
Items 7.01, 9.01
same SEC item: 7.01, 9.01
same event type: regulatory
similar materiality
Filing page
SEC filing
CDT
CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan
CDT Equity Inc.
May 28, 2026, 4:30 PM ET
regulatory
Items 3.01, 7.01, 9.01
same SEC item: 7.01, 9.01
same event type: regulatory
similar materiality
Filing page
SEC filing
TMC
NOAA certifies TMC USA's exploration license for USA B; 1.02B tonne nodule resource
TMC the metals Co Inc.
May 28, 2026, 9:04 AM ET
regulatory
Items 7.01, 9.01
same SEC item: 7.01, 9.01
same event type: regulatory
similar materiality
Filing page
SEC filing
BCDA
BioCardia Japan PMDA supports CardiAMP cell therapy submission for HFrEF; submission planned Q4 2026
BioCardia, Inc.
May 28, 2026, 8:00 AM ET
regulatory
Items 7.01, 9.01
same SEC item: 7.01, 9.01
same event type: regulatory
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.